// COMPANY
Link Cell Therapies
SECTOR BIOTECHMENTIONS 1LAST SEEN SEPTEMBER 30, 2026
// RECENT MENTIONS
// SIGNALS
1 SIGNAL
01
funding·StrictlyVC·SEPTEMBER 30, 2026
“Link Cell Therapies, CAR-T developer using marker-combination activation, raised a $30 million Series A round led by Johnson & Johnson with BMS participation.”
AI-extracted from podcast / newsletter / paper summaries. May contain errors.